Title:
癌の治療のためのネオアンチゲンワクチン組成物
Document Type and Number:
Japanese Patent JP7298926
Kind Code:
B2
Abstract:
The present invention provides a polypeptide comprising at least four different tumor-specific neo-antigens fused to, at least one T cell enhancer amino acid sequence, a nucleic acid sequence encoding such polypeptide, a vector comprising such nucleic acid sequence and a collection of vectors comprising such vectors. Further provided are compositions of matter comprising in admixture or separately a vaccine comprising the polypeptide, the nucleic acid sequence the vector or the collection of vectors of the invention and at least one modulator of a checkpoint molecule or another type of immunomodulator for use in treating cancer.
Inventors:
Nicosia, Alfredo
Skullselli, Eliza
Darise, Anna Morena
Skullselli, Eliza
Darise, Anna Morena
Application Number:
JP2020501243A
Publication Date:
June 27, 2023
Filing Date:
July 12, 2018
Export Citation:
Assignee:
Neuscom Arge
International Classes:
C12N15/12; A61K35/76; A61K38/16; A61K39/12; A61K39/42; A61K48/00; A61P35/00; A61P35/02; C07K14/47; C07K19/00; C12N15/62; C12N15/85; C40B40/08
Domestic Patent References:
| JP2014523406A | ||||
| JP2012509071A |
Foreign References:
| WO2017020026A1 | ||||
| WO2017060857A1 |
Other References:
Ugur Sahin,Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer,Nature,2017年07月05日,Vol. 547,p. 222-226
The Journal of Immunology,2008年,Vol. 180,p. 309-318,doi:10.4049/jimmunol.180.1.309
The Journal of Immunology,2008年,Vol. 180,p. 309-318,doi:10.4049/jimmunol.180.1.309
Attorney, Agent or Firm:
Takashi Shoji
Yuriko Sukenobu
Takuya Osugi
Hirata Midori
Yuriko Sukenobu
Takuya Osugi
Hirata Midori